obesity glp-1 news today drug october 2025 GLP-1 trends 2025: real-world data, patient outcomes & future therapies Dozens of new obesity drugs

The questions that remain unanswered include the actual prevalence of sexual side effects (we do not know if it affects 5 percent or 30 percent of women), whether certain doses are more likely to cause sexual dysfunction than others, whether compounded semaglutide formulations produce different sexual side effect profiles than brand-name versions, whether specific pharmacy sources or compounding pharmacies produce formulations with different tolerability profiles, and whether pre-treatment screening can identify women at higher risk for sexual dysfunction on GLP-1 agonists

Stick With ItDont Quit Too Early Nearly 1 in 4 people stop taking GLP-1s within the first 3 months

Dosage:5 pmol/min/kg

Marijuana food products can look just like regular foods

J Exerc Nutrition Biochem

After those were introduced, studies began to suggest they, too, had benefits which extended beyond their use in preventing heart attacks and strokes, such as lowering the risk of some types of cancer and perhaps protecting the brain from dementia